United States

Profile: Aptevo Therapeutics Inc (APVO.O)

APVO.O on Nasdaq

16 Jul 2019
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Aptevo Therapeutics Inc., incorporated on February 22, 2016, is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company's technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company's investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. The technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets.

The Company's marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)), VARIZIG (Varicella Zoster Immune Globulin (Human)), and IXINITY (coagulation factor IX (recombinant)). WinRho SDF is used for treatment of autoimmune platelet disorder, also called immune thrombocytopenic purpura (ITP), and separately, for the treatment of hemolytic disease of the newborn (HDN). HepaGam B is used for prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for treatment following exposure to hepatitis-B. VARIZIG is used for treatment following exposure to varicella zoster virus, which causes chickenpox. IXINITY is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and for management of bleeding during operations.


MOR209/ES414 is a targeted immunotherapeutic protein under development for metastatic castration-resistant prostate cancer. MOR209/ES414 is a bispecific ADAPTIR molecule that binds to prostate-specific membrane antigen (PSMA) and CD3. MOR209/ES414 contains two pairs of binding domains, one targeting the T-cell receptor (TCR), and one targeting PSMA on tumor cells. In pre-clinical studies, MOR209/ES414 has been shown to redirect T-cell cytotoxicity towards prostate cancer cells expressing PSMA.


ES210 is an anti-inflammatory molecule engineered using its ADAPTIR platform technology. It is under development for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease, and other autoimmune and inflammatory diseases. ES210 is a targeted cytokine therapeutic, specifically, it is designed to deliver a form of the anti-inflammatory cytokine, IL-10, to antigen presenting cells (APCs) that express CD86. The ES210 ADAPTIR molecule also has anti-inflammation applications in rheumatoid arthritis and in the treatment of transplant rejection.


ES425 is a bispecific ADAPTIR immunotherapeutic protein that targets ROR1, an antigen found on various solid tumors and hematologic, or blood-related, malignancies. One pair of binding domains bind to ROR1 on tumors; the other pair of binding domains bind to TCR. ES425 employs a mechanism of action that redirects T-cell cytotoxicity (RTCC), by which a therapeutic molecule brings T-cells into contact with tumor cells and triggers tumor killing, or targeted delivery of cytokines (or immune modulating protein) to diseased cells against tumors expressing ROR1. Initial preclinical data demonstrates redirected T-cell cytotoxicity activity. The Company focuses on conducting animal toxicology and pharmacokinetic studies.


Otlertuzumab is a monospecific protein therapeutic intended for the treatment of chronic lymphocytic leukemia (CLL). The Company has completed a Phase II clinical trial evaluating the combination of otlertuzumab and bendamustine (a chemotherapy agent) versus bendamustine alone in people with relapsed CLL (Study 16201).


5E3 is an investigational drug in preclinical development for the treatment of Alzheimer's disease and derived from a murine antibody. 5E3 is a humanized monoclonal antibody that selectively binds the oligomeric form of amyloid beta that have been associated with neurotoxicity.

The Company competes with CSL Limited, Amgen Inc., GlaxoSmithKline plc, Biotest Pharmaceuticals Corporation, Grifols USA, LLC, Baxter International Inc., Pfizer Inc., Biogen Idec Inc., Eisai Co. Ltd., Novartis Pharmaceuticals Corporation, Johnson & Johnson Health Care Systems Inc., Shionogi & Co., Ltd., Merz Pharma GMBH & Co. KGaA, Janssen Biotech, Inc., Eli Lilly and Company, and F. Hoffmann-La Roche Ltd.

Company Address

Aptevo Therapeutics Inc

2401 4th Ave Ste 1050
SEATTLE   WA   98121-3460
P: +1206.8380500
F: +1206.8380503

Company Web Links